(Q39487999)

English

The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jockenhövel F

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lederbogen S

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Olbricht T

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Schmidt-Gayk H

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Krenning EP

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lamberts SW

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Reinwein D

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

1 January 1994

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Journal of Molecular Medicine

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

127-133

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Circulating Glucagon Plasma Profiles and Metabolism in Health and Disease

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Biochemistry and physiology of gastrointestinal somatostatin

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Plasma immunoreactive glucagon fractions in four cases of glucagonoma: Increased “Large glucagon — immunoreactivity”

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Hormone-negative, chromogranin A-positive endocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Distribution of Plasma Glucagon Immunoreactivity in a Patient with Suspected Glucagonoma

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Radioimmunoassay of extracted glucagon compared with three non-extraction assays.

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Secretion by glucagonomas of a possible glucagon precursor

1 reference

https://api.crossref.org/works/10.1007%2FBF00184589

21 January 2018

Immunoluminometric assay of chromogranin A in serum with commercially available reagents

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic Studies and Glucagon Gel Filtration Pattern before and after Surgery in a Case of Glucagonoma Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Large glucagon immunoreactivity in extracts of pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unsuccessful DTIC treatment of a Patient with Glucagonoma Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure/Function and Structure/Immunoreactivity Relationships of the Glucagon Molecule and Related Synthetic Peptides

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8186658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00184589

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39487999&oldid=2202923173"